220 related articles for article (PubMed ID: 33296082)
21. Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation.
Spinthakis N; Gue Y; Farag M; Srinivasan M; Wellsted D; Arachchillage DRJ; Lip GYH; Gorog DA
Europace; 2019 Sep; 21(9):1297-1306. PubMed ID: 31505618
[TBL] [Abstract][Full Text] [Related]
22. Arterial Thrombus Stability: Does It Matter and Can We Detect It?
Gorog DA; Fayad ZA; Fuster V
J Am Coll Cardiol; 2017 Oct; 70(16):2036-2047. PubMed ID: 29025561
[TBL] [Abstract][Full Text] [Related]
23. Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study.
Sumaya W; Wallentin L; James SK; Siegbahn A; Gabrysch K; Himmelmann A; Ajjan RA; Storey RF
Thromb Haemost; 2020 Mar; 120(3):412-422. PubMed ID: 31975352
[TBL] [Abstract][Full Text] [Related]
24. Altered Plasma Clot Properties and Trauma-Related Venous Thromboembolism despite Thromboprophylaxis.
Goldman S; Frączek P; Szklanny K; Papuga-Szela E; Stanisz A; Undas A
Thromb Haemost; 2018 Apr; 118(4):654-663. PubMed ID: 29618152
[TBL] [Abstract][Full Text] [Related]
25. Altered fibrin clot structure/function in patients with antiphospholipid syndrome: association with thrombotic manifestation.
Celińska-Lowenhoff M; Iwaniec T; Padjas A; Musiał J; Undas A
Thromb Haemost; 2014 Aug; 112(2):287-96. PubMed ID: 24652596
[TBL] [Abstract][Full Text] [Related]
26. Fibrin clot properties and their modulation in thrombotic disorders.
Undas A
Thromb Haemost; 2014 Jul; 112(1):32-42. PubMed ID: 24671700
[TBL] [Abstract][Full Text] [Related]
27. Fibrinolysis and the risk of venous and arterial thrombosis.
Meltzer ME; Doggen CJ; de Groot PG; Rosendaal FR; Lisman T
Curr Opin Hematol; 2007 May; 14(3):242-8. PubMed ID: 17414214
[TBL] [Abstract][Full Text] [Related]
28. Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention.
Christopoulos C; Farag M; Sullivan K; Wellsted D; Gorog DA
Thromb Haemost; 2017 Feb; 117(3):457-470. PubMed ID: 28004059
[TBL] [Abstract][Full Text] [Related]
29. Effect of P2Y
Spinthakis N; Farag M; Gue YX; Srinivasan M; Wellsted DM; Gorog DA
Thromb Res; 2019 Jan; 173():102-108. PubMed ID: 30500673
[TBL] [Abstract][Full Text] [Related]
30. Dynamic Hemostasis and Fibrinolysis Assays in Intensive Care COVID-19 Patients and Association with Thrombosis and Bleeding-A Systematic Review and a Cohort Study.
Hvas CL; Larsen JB; Adelborg K; Christensen S; Hvas AM
Semin Thromb Hemost; 2022 Feb; 48(1):31-54. PubMed ID: 34715692
[TBL] [Abstract][Full Text] [Related]
31. Fibrinolysis in Acute and Chronic Cardiovascular Disease.
Kietsiriroje N; Ariëns RAS; Ajjan RA
Semin Thromb Hemost; 2021 Jul; 47(5):490-505. PubMed ID: 33878782
[TBL] [Abstract][Full Text] [Related]
32. Blood Accessibility to Fibrin in Venous Thrombosis is Thrombus Age-Dependent and Predicts Fibrinolytic Efficacy: An In Vivo Fibrin Molecular Imaging Study.
Stein-Merlob AF; Kessinger CW; Erdem SS; Zelada H; Hilderbrand SA; Lin CP; Tearney GJ; Jaff MR; Reed GL; Henke PK; McCarthy JR; Jaffer FA
Theranostics; 2015; 5(12):1317-27. PubMed ID: 26516370
[TBL] [Abstract][Full Text] [Related]
33. Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome.
Vikerfors A; Svenungsson E; Ågren A; Mobarrez F; Bremme K; Holmström M; Eelde A; Bruzelius M; Elgue G; Wallén H; Antovic A
Thromb Res; 2014 May; 133(5):936-44. PubMed ID: 24630645
[TBL] [Abstract][Full Text] [Related]
34. Risk of future arterial cardiovascular events in patients with idiopathic venous thromboembolism.
Green D
Hematology Am Soc Hematol Educ Program; 2009; ():259-66. PubMed ID: 20008208
[TBL] [Abstract][Full Text] [Related]
35. Enhanced spontaneous thrombolysis: a new therapeutic challenge.
Kovacs IB; Gorog DA; Yamamoto J
J Thromb Thrombolysis; 2006 Jun; 21(3):221-7. PubMed ID: 16683213
[TBL] [Abstract][Full Text] [Related]
36. Tissue plasminogen activator release and plasminogen activator inhibitor levels in coronary artery disease.
Meyers DG; Haire WD; Rasmussen JK; Boyd EJ
Angiology; 1991 Jul; 42(7):561-7. PubMed ID: 1907440
[TBL] [Abstract][Full Text] [Related]
37. Fibrinolysis and thrombosis.
Booth NA; Bennett B
Baillieres Clin Haematol; 1994 Sep; 7(3):559-72. PubMed ID: 7841601
[TBL] [Abstract][Full Text] [Related]
38. Prolonged clot lysis time increases the risk of a first but not recurrent venous thrombosis.
Karasu A; Baglin TP; Luddington R; Baglin CA; van Hylckama Vlieg A
Br J Haematol; 2016 Mar; 172(6):947-53. PubMed ID: 26773756
[TBL] [Abstract][Full Text] [Related]
39. A new assay for global fibrinolysis capacity (GFC): Investigating a critical system regulating hemostasis and thrombosis and other extravascular functions.
Amiral J; Laroche M; Seghatchian J
Transfus Apher Sci; 2018 Feb; 57(1):118-126. PubMed ID: 29525568
[TBL] [Abstract][Full Text] [Related]
40. Fibrinolysis Shutdown Is Associated With Thrombotic and Hemorrhagic Complications and Poorer Outcomes After Liver Transplantation.
Nicolau-Raducu R; Beduschi T; Vianna R; Diez C; Sleem M; Singh BP; Vasileiou G; Raveh Y
Liver Transpl; 2019 Mar; 25(3):380-387. PubMed ID: 30548128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
